Close menu




September 18th, 2025 | 07:25 CEST

Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!

  • AI
  • Biotechnology
  • Technology
  • Sportswear
  • Investments
Photo credits: PUMA

Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: NETRAMARK HOLDINGS INC | CA64119M1059 , PUMA SE | DE0006969603 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    NetraMark Holdings: 50% upside potential

    NetraMark shares currently offer an attractive entry opportunity. After a failed breakout attempt from its sideways trend, shares of the Canadian AI specialist, which are also traded on Tradegate, are now trading at CAD 1.48. The price target set by analysts at Zacks Small-Cap Research is CAD 2.25, meaning an upside potential of around 50%. Pharma and biotech companies can save billions in drug development using NetraMark's proprietary AI platform, NetraAI. The software improves efficiency, precision, and regulatory compliance of clinical trials through AI-driven analytics. For context: McKinsey management consultants estimate that the pharmaceutical industry spent around USD 247 billion on research and development in 2022. The savings potential is therefore enormous.

    General AI systems such as ChatGPT and DeepSeek appear to reach their limits when it comes to these highly specific tasks. NetraAI outperformed both in a comparative test. The results published in July showed that NetraAI outperforms its competitors in the analysis of real-world, highly complex clinical trial data. NetraMark AI was the only one to identify reliable, clinically actionable insights in three independent studies on schizophrenia, depression, and pancreatic cancer. The accuracy of its predictions of treatment outcome exceeded 90% in some cases. ChatGPT and DeepSeek were only able to produce unusable clusters or generic texts.

    NetraAI is already being used in practice. Among other things, a global agreement was signed with CRO Worldwide Clinical Trials in April 2025. The contract research organization conducts clinical trials for pharmaceutical and biotech companies worldwide and offers customers the NetraAI platform to optimize their studies. In addition, several pharmaceutical and biotech companies are already relying on NetraMark's AI. These include Asklepion Pharmaceuticals, for example. They are using the NetraAI platform in a pivotal pediatric Phase III trial on the efficacy of intravenous L-citrulline (CIT-003-01) for the prevention of acute lung injury in children.

    Puma: Merger with Adidas a crazy idea?

    Are Puma and Adidas merging? This sounds both spectacular and crazy at the same time. After all, the two sporting goods manufacturers are archrivals. The tensions date back to the split between the Dassler brothers in Herzogenaurach in 1948. To this day, they regularly poach each other's top managers. Yet, it was precisely this idea of a merger that Roy Adams recently floated in an interview with Handelsblatt. From the perspective of the manager of US investor Metronuclear, Adidas should take advantage of the difficult situation of its smaller competitor and swallow Puma. Adams explained that Puma was in a "state of emergency" - its share price has fallen sharply this year, operating performance is weak, and if management fails to take adequate measures, a merger with Adidas would be the best option. This speculation caused a media stir, but only led to a slight rise in the Puma share price. The muted reaction suggests that investors are not convinced the idea will materialize.

    There were plenty of comments on the proposal. Opinions differ. Some see potential, while others warn of practical and strategic hurdles. Analysts at DZ Bank, for example, believe that the idea of a merger has "a certain charm at first glance" - precisely because of the historical connection between the two companies. But on closer inspection, there is little concrete benefit for Adidas. Instead, there is a risk of cannibalization, as the brands are positioned very similarly. The integration of such a large acquisition also carries significant risks.

    JPMorgan warns of the difficulty of adequately managing a turnaround program and the merger at the same time. The effort and complexity would be too great for Adidas. There is a lot of overlap between the brands. In addition, the costs of standardizing brands, logistics, and distribution are difficult to estimate.

    Overall, many experts agree that the idea is exciting, but so far, there are no signs that Adidas is pursuing a concrete merger plan. Uncertainty about costs, brand integration, and shareholder interests remains high.

    Evotec: Another insider purchase

    Are we seeing a tentative attempt at recovery in Evotec shares with the rise above the EUR 6 mark? In any case, it is too early to speak of a trend reversal. In recent weeks, the German biotech company's shares have been characterized by a mixture of negative impulses and short-term attempts at recovery. The last major sell-off was triggered in July by the reduction of the revenue forecast of EUR 760 million to EUR 800 million (previously: EUR 840 million to EUR 880 million). This was followed by a decline in the share price from EUR 7.46 to EUR 5.70. To put this into context: In October 2021, the share price of the former German biotech hope stood at around EUR 45.

    At least top management appears to see the current level as an opportunity to buy. On August 27, 2025, CEO Christian Wojczewski purchased shares worth just under EUR 300,000. The price was EUR 5.92 per share. A few days ago, fellow board member Paul Hitchin also made a move. He bought Evotec shares worth around EUR 74,000 at a price of EUR 5.91.

    Insider purchases are generally seen as a sign that executives have confidence in the Company's medium-term prospects. At Evotec, the share price has not yet recovered sustainably. Perhaps management will be able to convince investors in the coming week. On September 22, Evotec will participate in the virtual CMO conference and the following day in the German Corporate Conference hosted by Berenberg and Goldman Sachs in Munich.


    Based on its operational performance, there is a good chance that NetraMark shares will reach the analysts' price target. This would represent a 50% upside potential. However, the sideways trend must first be broken. Economically, the idea of a merger between Puma and Adidas is justified, especially if Puma is unable to overcome its crisis on its own. In practice, however, the integration risks would be enormous. Insider purchases at Evotec are certainly a positive signal, but more is needed for a sustained upward trend.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 20th, 2026 | 05:55 CET

    Two sides of the same coin: America's legacy liabilities are Zefiro's opportunity! Analysts are extremely bullish!

    • Methane
    • Oil and gas
    • Orphan Wells
    • Climate change
    • Investments

    Created and published on behalf of Zefiro Methane Corp.

    Over a period of 20 years, methane has around 80 times the global warming impact of the same mass of CO₂. Preventing methane emissions can therefore deliver results relatively quickly. This explains the political focus on leaks and the plugging of abandoned and orphaned wells. Under the Infrastructure Investment and Jobs Act (IIJA), the US government has earmarked around USD 4.7 billion to plug and remediate orphan wells. "Orphan" means that no responsible operator can be held accountable. One lesser-known beneficiary of this situation is Zefiro Methane. The company is an established hidden champion in the US and is steadily expanding its business both organically and through acquisitions. Having recently secured fresh capital, the company could soon be stepping up its operations significantly. Analysts see substantial share price upside.

    Read

    Commented by Carsten Mainitz on November 20th, 2026 | 05:55 CET

    Gold Below USD 4,000! Central Bank Buying at Record Highs! What Matters Now for Kobo Resources, Barrick and Deutsche Börse!

    • Gold
    • Precious metals
    • Explorer
    • Gold producer
    • Xetra-Gold
    • Stock exchange
    • Investments
    • Real assets
    • Interest rates
    • Inflation
    • US dollar
    • Safe-haven currency

    Central banks are massively increasing their gold reserves, yet the price is falling to a 14-month low. The World Gold Council estimates net purchases in the third quarter at 321 tonnes. China's central bank bought 26 tonnes of gold in October alone, the largest monthly purchase in three years. But why is the price of the precious metal falling? The explanation lies in the bond market, among other factors. Signals from the US Federal Reserve make further interest rate rises more likely. The US dollar also strengthened. However, long-term investors should remain calm. Central bank purchases and its role as a safe-haven currency amid spiralling government debt are ultimately the most compelling arguments. Goldman Sachs sees a price target of USD 4,650 by the end of 2027. How should investors position themselves now - explorer, producer or product?

    Read